Clinical laboratory parameters before treatment and maximal absolute changes during treatment
| Variable . | Hemoglobin . | Reticulocytes . | Bilirubin . | Haptoglobin . | Lactate dehydrogenase . | Complement C4 . | CA titer . |
|---|---|---|---|---|---|---|---|
| Normal range | 12-16 g/dL | 32-110 × 109/L | 0.1-1.2 mg/dL | 30-200 mg/dL | <250 U/L | 0-40 mg/mL | 1-32 titer |
| Patient | |||||||
| C1001 | 8.3/+3.8 | 131/−100 | 1.6/−1.4 | <12/+55.4 | 212/−40 | 10.9/+20.8 | 512/−384 |
| C1002 | 7.5/+4.8 | 140/−114 | 2.5/−2.1 | <12/+30.5 | 375/−185 | 14.5/+23.1 | 32/+32* |
| C1003 | 7.9/+0.5 | 133/−62 | 0.9/−0.2 | <12/0 | 537/−96 | 7.0/0† | 1024/−512 |
| C1004 | 6.8/+4.0 | 101/−65 | 1.7/−1.4 | <12/+121 | 501/−334 | 7.0/+21.4 | 1024/0 |
| C1006 | 7.7/+4.5 | 171/NA | 3.8/−3.0 | <12/0 | 371/−133 | 7.0/+18.2 | 1024/0 |
| C1008 | 8.2/+5.0 | 115/−68 | 4.8/−4.3 | <12/+96 | 357/−194 | 7.0/+19.6 | 256/+768 |
| C1009 | 6.1/+3.7 | NA/NA | 6.7/−1.4‡ | <12/0 | 342/−57 | 7.0/+9.3 | 1024/0 |
| C1010 | 7.6/+4.0 | 136/−60 | 2.2/−1.6 | <12/0 | 506/−190 | 20.4/+21.6 | 1024/0 |
| C1011 | 9.3/+1.3 | 183/−70 | 1.7/−0.7 | <12/5.5 | 309/−34 | 14.1/+20.4 | 512/+512 |
| C1013 | 10.4/+0.9 | 125/−96 | 1.0/−0.7 | <12/0 | 352/−38 | 7.0/+14.3 | 1024/0 |
| Median/change | 7.8/3.9 | 133/−97 | 2.0/−1.5 | <12/3 | 364/−174 | 7.0/+19.6 | 1024/16 |
| Variable . | Hemoglobin . | Reticulocytes . | Bilirubin . | Haptoglobin . | Lactate dehydrogenase . | Complement C4 . | CA titer . |
|---|---|---|---|---|---|---|---|
| Normal range | 12-16 g/dL | 32-110 × 109/L | 0.1-1.2 mg/dL | 30-200 mg/dL | <250 U/L | 0-40 mg/mL | 1-32 titer |
| Patient | |||||||
| C1001 | 8.3/+3.8 | 131/−100 | 1.6/−1.4 | <12/+55.4 | 212/−40 | 10.9/+20.8 | 512/−384 |
| C1002 | 7.5/+4.8 | 140/−114 | 2.5/−2.1 | <12/+30.5 | 375/−185 | 14.5/+23.1 | 32/+32* |
| C1003 | 7.9/+0.5 | 133/−62 | 0.9/−0.2 | <12/0 | 537/−96 | 7.0/0† | 1024/−512 |
| C1004 | 6.8/+4.0 | 101/−65 | 1.7/−1.4 | <12/+121 | 501/−334 | 7.0/+21.4 | 1024/0 |
| C1006 | 7.7/+4.5 | 171/NA | 3.8/−3.0 | <12/0 | 371/−133 | 7.0/+18.2 | 1024/0 |
| C1008 | 8.2/+5.0 | 115/−68 | 4.8/−4.3 | <12/+96 | 357/−194 | 7.0/+19.6 | 256/+768 |
| C1009 | 6.1/+3.7 | NA/NA | 6.7/−1.4‡ | <12/0 | 342/−57 | 7.0/+9.3 | 1024/0 |
| C1010 | 7.6/+4.0 | 136/−60 | 2.2/−1.6 | <12/0 | 506/−190 | 20.4/+21.6 | 1024/0 |
| C1011 | 9.3/+1.3 | 183/−70 | 1.7/−0.7 | <12/5.5 | 309/−34 | 14.1/+20.4 | 512/+512 |
| C1013 | 10.4/+0.9 | 125/−96 | 1.0/−0.7 | <12/0 | 352/−38 | 7.0/+14.3 | 1024/0 |
| Median/change | 7.8/3.9 | 133/−97 | 2.0/−1.5 | <12/3 | 364/−174 | 7.0/+19.6 | 1024/16 |
For haptoglobin, 11 mg/dL was used for calculations when <12 mg/dL. Cold agglutinin (CA) titers indicate fold-dilutions (1024 maximum tested).
C4, complement component 4 (7 was used for calculations when <8 mg/dL); NA, not assessable due to agglutination.
The cold agglutinin titer was 1:64 during screening.
Patient with complement deficiency and 70% bone marrow infiltration whose hemoglobin values were censored before start of ibrutinib for conservative statistical comparison.
Gilbert disease.